AlzChem Group Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Andreas Niedermaier
Chief executive officer
€1.5m
Total compensation
| CEO salary percentage | 20.9% |
| CEO tenure | 13.2yrs |
| CEO ownership | n/a |
| Management average tenure | 7.1yrs |
| Board average tenure | 11.6yrs |
Recent management updates
Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01
AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05Recent updates
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
Nov 14AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
Oct 27When Should You Buy AlzChem Group AG (ETR:ACT)?
Oct 18AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Sep 07A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Jun 04AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
May 08Shareholders Will Probably Hold Off On Increasing AlzChem Group AG's (ETR:ACT) CEO Compensation For The Time Being
May 01AlzChem Group's (ETR:ACT) Upcoming Dividend Will Be Larger Than Last Year's
Apr 26Is AlzChem Group (ETR:ACT) A Risky Investment?
Apr 11AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.20
Mar 29The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | €50m |
| Jun 30 2024 | n/a | n/a | €46m |
| Mar 31 2024 | n/a | n/a | €39m |
| Dec 31 2023 | €2m | €315k | €35m |
| Sep 30 2023 | n/a | n/a | €30m |
| Jun 30 2023 | n/a | n/a | €28m |
| Mar 31 2023 | n/a | n/a | €30m |
| Dec 31 2022 | €818k | €315k | €30m |
| Sep 30 2022 | n/a | n/a | €29m |
| Jun 30 2022 | n/a | n/a | €28m |
| Mar 31 2022 | n/a | n/a | €27m |
| Dec 31 2021 | €890k | €300k | €28m |
| Sep 30 2021 | n/a | n/a | €27m |
| Jun 30 2021 | n/a | n/a | €26m |
| Mar 31 2021 | n/a | n/a | €23m |
| Dec 31 2020 | €786k | €300k | €20m |
| Sep 30 2020 | n/a | n/a | €16m |
| Jun 30 2020 | n/a | n/a | €17m |
| Mar 31 2020 | n/a | n/a | €17m |
| Dec 31 2019 | €915k | €260k | €18m |
| Sep 30 2019 | n/a | n/a | €19m |
| Jun 30 2019 | n/a | n/a | €18m |
| Mar 31 2019 | n/a | n/a | €20m |
| Dec 31 2018 | n/a | n/a | €23m |
| Sep 30 2018 | n/a | n/a | €22m |
| Jun 30 2018 | €453k | €110k | €32m |
| Mar 31 2018 | n/a | n/a | €21m |
| Dec 31 2017 | €1m | €220k | €20m |
Compensation vs Market: Andreas's total compensation ($USD1.58M) is about average for companies of similar size in the German market ($USD1.44M).
Compensation vs Earnings: Andreas's compensation has increased by more than 20% in the past year.
CEO
Andreas Niedermaier (55 yo)
13.2yrs
Tenure
€1,509,000
Compensation
Mr. Andreas Niedermaier has been Chairman of Executive Board & Chief Executive Officer at AlzChem Group AG since July 01, 2019 and has been its Member of Management Board since October 20, 2011. He served...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of Executive Board | 13.2yrs | €1.51m | no data | |
| Member of Executive Board & COO | 8.8yrs | €1.24m | no data | |
| Chief Sales Officer & Member of Executive Board | 5.4yrs | €1.24m | no data | |
| CFO & Member of Management Board | less than a year | no data | no data |
7.1yrs
Average Tenure
59yo
Average Age
Experienced Management: ACT's management team is seasoned and experienced (7.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Supervisory Board | 15.2yrs | €42.00k | no data | |
| Independent Member of the Supervisory Board | 8.1yrs | €24.00k | no data | |
| Deputy Chairman of the Supervisory Board | 8.1yrs | €32.00k | no data | |
| Member of the Supervisory Board | 15.2yrs | €22.00k | no data |
11.6yrs
Average Tenure
53.5yo
Average Age
Experienced Board: ACT's board of directors are seasoned and experienced ( 11.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 00:52 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AlzChem Group AG is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Lopez Pineda | Baader Helvea Equity Research |
| Konstantin Wiechert | Baader Helvea Equity Research |
| Knut Woller | Baader Helvea Equity Research |